RU2125389C1 - Biologically active food addition - Google Patents

Abstract

FIELD: food industry, dietetics. SUBSTANCE: biologically active addition has human recombinant alpha-2-interferon at dose 10³-10⁹ IU/1 g acceptable foodstuff as an immunobiological preparation. It can contain immunoglobulins at mass ratio immunoglobulins : foodstuff = (100:1)-(1:1000) additionally. The use of biologically active addition in foodstuff ensures to prolong and enhance an effect of human alpha-2-interferon. EFFECT: enhanced effectiveness of an addition, prolonged effect. 7 ex

Description

 The invention relates to medicine, dietetics and can be, in particular, used in clinical nutrition.

 From the practice of medicine, biologically active food additives, including immunobiological preparations, are known [1].

 They are used to increase immunological reactivity and normalize intestinal biocenosis.

 The closest analogue (prototype) of the claimed biologically active food supplement is a biologically active supplement with immune lactoglobulin, which is made from colostrum of cows and contains antibodies to enteropathogenic Escherichia coli and proteins (BA-IG). The proportion of immunoglobulins in a known dietary supplement is 5% [1].

The disadvantages of the known biologically active additives are:
- the use of animal immunoglobulins, which increases the risk of allergic reactions;
- the inability to use the known biologically active additives in the presence of an allergic reaction to milk proteins or to gammaglobulins;
- insufficiently consistent composition of the humoral anti-infectious factors of the known biologically active additives to human milk.

 The inventive biologically active food supplement is new and is not described in the literature.

 The technical result is the prolongation and intensification of the action of human recombinant alpha-2-interferon due to its stabilization by means of a food product, as well as due to an optimally selected amount and proportion.

The problem is solved in that, as an immunobiological preparation, a biologically active food supplement contains human recombinant alpha-2-interferon at the rate of 10 ³ - 10 ⁹ IU per 1 g of an acceptable food product.

 Preferably, the biologically active additive additionally contains human immunoglobulins at a mass ratio of human immunoglobulins: food product equal to 100: 1-1: 1000.

 As human immunoglobulins, already known immunoglobulin preparations can be used, in particular CIP (complex immunoglobulin preparation) containing a mixture of human immunoglobulins: IgA, IgG, IgM.

 The mass fraction of human recombinant alpha-2-interferon was not taken into account, since its mass in a biologically active additive does not exceed 10-50 μg.

 The authors took into account the results of their own studies, proving the presence of various biological properties of human recombinant alpha-2-interferon (antiviral, antichlamydia, antibacterial, immunomodulatory effects, the ability to normalize intestinal microbiocenosis) and the presence of in vitro synergistic action when combined human recombinant alpha-2-interferon with human immunoglobulins. The food product allows longer to maintain the activity of interferon in the aggressive secretion of the digestive tract.

Example 1. The inventive biologically active additive in the form of a powdered product includes human recombinant alpha-2-interferon at the rate of 10 ⁹ IU per 1 g of albumin.

In a clinical study, the dietary supplement was dissolved in Baby and given to an artificially fed 2-month-old child with acute respiratory disease complicated by acute bronchitis resistant to treatment for 5 days with a daily dose of interferon of 10 ⁶ IU. A decrease in the intensity of clinical signs of the disease was established on the second day of clinical nutrition, their full resolution on the fourth day.

Example 2. The inventive biologically active additive in the form of a liquid product includes human recombinant alpha-2-interferon at the rate of 10 ⁶ IU per 1 g of product.

In a clinical study, a biologically active supplement was given inside a 6-month-old baby who was breast-fed (contact with patients with an acute respiratory illness by her brother and mother) to prevent respiratory infection for 5 days at a daily dose of interferon of 10 ⁶ IU. During the first 3 days, the dietary supplement was prepared on the basis of kefir, during the next 2 days - on the basis of fruit jelly. The child did not get sick.

Example 3. The inventive biologically active additive in the form of a liquid product includes human recombinant alpha-2-interferon at the rate of 10 ³ IU per 1 g of pasteurized breast milk.

In a clinical study, a biologically active supplement was given orally to a mixed-fed child with toxic allergic derma at the age of 6 months for 5 days at a daily dose of interferon of 10 ⁶ IU. Antihistamines have not been used. The resolution of the clinical signs of toxicoallergic derma has been established.

Example 4. The inventive biologically active additive in the form of a powdery product includes human recombinant alpha-2-interferon at a rate of 10 ⁶ IU per 1 g of product, human immunoglobulins and albumin in a weight ratio of human immunoglobulins: albumin equal to 100: 1.

In a clinical study, the dietary supplement was dissolved in the “Baby” mixture and given to a 5-month-old infant who was artificially fed with a food allergy. The child was diagnosed with intestinal dysbiosis. The course of treatment was 5 days with a daily dose of interferon 10 ⁶ IU. The resolution of the clinical signs of the disease and the normalization of intestinal microbiocenosis have been achieved.

Example 5. The inventive biologically active additive in the form of a liquid product includes human recombinant alpha-2-interferon at the rate of 10 ⁵ IU per 1 g of product, human immunoglobulins and cow's milk with a mass ratio of human immunoglobulins: cow's milk equal to 1:10.

In a clinical study, a dietary supplement was given inside an 8-month-old artificially fed child with acute respiratory illness. The course of treatment was 5 days with a daily dose of interferon 10 ⁶ IU. The resolution of the clinical signs of the disease has been achieved.

Example 6. The inventive biologically active additive in the form of a liquid product includes human recombinant alpha-2-interferon at the rate of 10 ³ IU per 1 g of product, human immunoglobulins and cow's milk with a weight ratio of human immunoglobulins: cow's milk equal to 1: 1000.

In a clinical study, a dietary supplement was given inside an 8-month-old artificially fed child with acute respiratory illness. The course of treatment was 5 days with a daily dose of interferon 10 ⁶ IU. The resolution of the clinical signs of the disease has been achieved.

Example 7. The inventive biologically active additive in the form of a liquid product includes human recombinant alpha-2-interferon at the rate of 10 ⁴ IU per 1 g of food product (milk or fruit jelly) and human immunoglobulins with a mass ratio of human immunoglobulins: food product equal to 1: 1000.

In a clinical study, a dietary supplement was given orally to a patient aged 32 years with viral esophagitis. The course of treatment was 7 days with a daily dose of interferon 10 ⁶ IU. The resolution of the clinical signs of the disease has been achieved.

Sources of information
Kuvaeva I.B., Ladodo K.S. Microecological and immune disorders in children: Dietary correction. - M .: Medicine, 1991. - p. 67-73. 3

Claims (2)

1. A biologically active food supplement, including an immunobiological preparation, characterized in that as an immunobiological preparation it contains human recombinant alpha-2-interferon at a rate of 10 ³ - 10 ⁹ IU per 1 g of an acceptable food product.  2. The additive according to claim 1, characterized in that it further comprises human immunoglobulins, with a mass ratio of human immunoglobulins: food product equal to 100: 1 - 1: 1000.